You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Woodward Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for WOODWARD, and what generic and branded alternatives to WOODWARD drugs are available?

WOODWARD has seven approved drugs.

Summary for Woodward

US Patents:	0
Tradenames:	8
Ingredients:	6
NDAs:	7

Drugs and US Patents for Woodward

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Woodward	MIVACURIUM CHLORIDE	mivacurium chloride	SOLUTION;INTRAVENOUS	209708-002	Oct 12, 2021		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Woodward	MIVACURIUM CHLORIDE	mivacurium chloride	SOLUTION;INTRAVENOUS	209708-001	Oct 12, 2021		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Woodward	FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	fluconazole	INJECTABLE;INJECTION	077909-002	May 26, 2010	AP	RX	No	No		⤷ Sign Up				⤷ Sign Up
Woodward	MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER	milrinone lactate	INJECTABLE;INJECTION	077151-001	Jul 20, 2005		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Woodward	FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER	fluconazole	INJECTABLE;INJECTION	077988-001	May 26, 2010		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Woodward	FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER	fluconazole	INJECTABLE;INJECTION	077988-002	May 26, 2010		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Woodward Specl	DECA-DURABOLIN	nandrolone decanoate	INJECTABLE;INJECTION	013132-003	Jun 12, 1986		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Woodward

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Woodward	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-004	May 25, 1999	5,741,803*PED	⤷ Sign Up
Woodward	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-004	May 25, 1999	5,002,953*PED	⤷ Sign Up
Woodward	LOVAZA	omega-3-acid ethyl esters	CAPSULE;ORAL	021654-001	Nov 10, 2004	5,502,077	⤷ Sign Up
Woodward	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-002	May 25, 1999	5,002,953*PED	⤷ Sign Up
Woodward	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-002	May 25, 1999	5,741,803*PED	⤷ Sign Up
Woodward	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-003	May 25, 1999	5,002,953*PED	⤷ Sign Up
Woodward	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-002	May 25, 1999	7,358,366*PED	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for WOODWARD drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	1 g	➤ Subscribe	2008-11-10

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.